openPR Logo
Press release

Precise Analysis on Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) Clinical Trials Reviewed for H1, 2017

06-29-2017 05:18 PM CET | Health & Medicine

Press release from: Pharmaceutical Research Reports [MRH]

Pharmaceutical Industry Research Reports - MRH

Pharmaceutical Industry Research Reports - MRH

The latest report Metabotropic Glutamate Receptor 7 - Pipeline Review, H1 2017, outlays comprehensive information on the Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics development with respective active and dormant or discontinued projects.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1196639

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Metabotropic glutamate receptor 7 is a protein encoded by the GRM7 gene. G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase.

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 3 and 1 respectively. Report covers products from therapy areas Central Nervous System, Ear Nose Throat Disorders and Genetic Disorders which include indications Post-Traumatic Stress Disorder (PTSD), Anxiety Disorders, Acute Sensorineural Hearing Loss, Acute Stress Disorder, Attention Deficit Hyperactivity Disorder (ADHD), Autism, DiGeorge Syndrome, Generalized Anxiety Disorder (GAD), Infantile Spasm (West Syndrome), Obsessive-Compulsive Disorder, Presbycusis, Status Epilepticus, Substance (Drug) Abuse and Visceral Pain.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Make An Enquiry: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1196639

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)
- The report reviews Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Browse Full Report With TOC: http://www.marketresearchhub.com/report/metabotropic-glutamate-receptor-7-gprc1g-or-mglur7-or-grm7-pipeline-review-h1-2017-report.html

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/
Read Industry News At: https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Precise Analysis on Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) Clinical Trials Reviewed for H1, 2017 here

News-ID: 601552 • Views: 143

More Releases from Pharmaceutical Research Reports [MRH]

Pipeline Analysis on Phenylalanine 4 Hydroxylase Reviewed by Company, Profiled D …
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) - Pipeline Review, H1 2017”. This research study outlays comprehensive information on the Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration
Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopepti …
According to the latest pipeline analysis, Aminopeptidase N (APN/CD13) acts as an exopeptidase and has been studied for decades. In recent years, it has been seen not only as a tumor-related target but also as a potential functional protein in various other physiological or pathological processes, such as analgesia, virus infection and inflammation. To elaborate further details on its global demand, a study titled “Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein
Global Indoleamine 2, 3 Dioxygenase 1 Industry Vital Pipeline Review for the Fir …
The indoleamine 2, 3 Dioxygenase 1 or IDO1 market is developing since the cancer treatment sector relies heavily on its’ in-depth research and high-quality treatments. Looking into this huge potential, a new study has been added to the vast online repository of Market Research Hub (MRH), with the title ‘’Indoleamine 2, 3 Dioxygenase 1 (Indoleamine Pyrrole 2, 3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Pipeline Review, H1 2017‘’.
Prosthetic Joint Infections - Clinical Trials Rise Due to Higher Disease Inciden …
Market Research HUB's Pharmaceutical and Healthcare latest pipeline guide Prosthetic joint infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Prosthetic joint infections (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news

All 5 Releases


More Releases for Metabotropic

Metabotropic Glutamate Market Analysis & Forecast 2019| Aevi Genomic Medicine In …
Los Angeles, United State, April 16, 2019- The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the global Metabotropic Glutamate market. It includes Porter’s Five Forces and PESTLE analysis to equip your business with critical information and comparative data about the Global Metabotropic Glutamate Market. We have provided deep analysis of
Metabotropic Glutamate Receptor 3 Market Overview, Growth Analysis, Share, Oppor …
In 2018, the global Metabotropic Glutamate Receptor 3 market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. In this study, 2017 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for Metabotropic Glutamate Receptor 3. This report focuses on the key data information of Metabotropic Glutamate Receptor 3 in
Global Metabotropic Glutamate Receptor 7 Sales Market Size, Analysis, Growth & F …
A fresh report has been added to the wide database of Market Research Hub (MRH) titled “Global Metabotropic Glutamate Receptor 7 Market Research Report 2018” which provides an outlook for current market value as well as the expected forecast including Rate on Investment (ROI) together with growing CAGR of XX% during 2018-2025. The report studies the metabotropic glutamate receptor 7 sales market worldwide, especially in North America, China, Europe, Southeast
Global Metabotropic Glutamate Receptor 7 Market Research Report 2017
The market for pharmaceutical industry is growing with the expansion of this Industry Sector Worldwide. Market Research Hub (MRH) has added a new report titled “Global Metabotropic Glutamate Receptor 7 Market Research Report 2017”which offer details about the current trends and analysis, as well as scope for the near future. This research study also covers information about the production, consumption and market share based on different active regions. Furthermore, an
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, …
ReportsWorldwide has announced the addition of a new report title Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Metabotropic glutamate receptor 5 (mGluR5) is a G protein-coupled receptor. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, …
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2017”. Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. Request For Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1305498 The latest report Metabotropic Glutamate